BiotechTube
ChiRhoClin

ChiRhoClin

Burtonsville, United States· Est.
chirhoclin.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 1991 by Dr. Edward D. Purich, ChiRhoClin is a specialized pharmaceutical company dedicated to orphan theranostics for gastrointestinal and pancreatic disorders. Its core achievement is the FDA approval and commercialization of ChiRhoStim® (Synthetic Human Secretin), used in diagnostic pancreatic function tests and to facilitate endoscopic retrograde cholangiopancreatography (ERCP). The company maintains a research-oriented culture, supports academic research through grant programs, and collaborates with major medical institutions on ongoing clinical studies in pancreatic cancer and pancreatitis.

GastroenterologyPancreatic DiseasesOncology

Technology Platform

Specialization in the synthetic production and clinical application of the peptide hormone secretin for diagnostic (pancreatic function testing) and therapeutic (facilitation of endoscopic procedures) uses in gastrointestinal and pancreatic diseases.

Opportunities

Growth opportunities include expanding the evidence base and approved indications for ChiRhoStim® through supported clinical research, particularly in early pancreatic cancer detection.
The company can also leverage its CRO services and academic network to in-license or co-develop additional orphan theranostic products for gastrointestinal diseases.

Risk Factors

Key risks include heavy reliance on a single product family (secretin), a potentially limited total addressable market for its niche applications, and the lack of a visible internal pipeline of novel drug candidates.
As a private, family-run business, succession planning is also a consideration.

Competitive Landscape

ChiRhoClin faces limited direct competition for its FDA-approved synthetic human secretin in its specific ERCP facilitation and pancreatic function test indications. Broader competition exists from alternative diagnostic modalities (imaging, other tests) and the standard of performing ERCP without pharmacological aid. Its differentiation lies in its specialized expertise, orphan drug status, and deep integration with the clinical and academic gastroenterology community.

More companies in Diagnostics & Precision Medicine →More companies in United States →